Form 4: Neuphoria Therapeutics Director, Peter Miles Winston Davies, Acquires Restricted Stock Units

Director Peter Miles Winston Davies acquired 6,783 Restricted Stock Units (RSUs) of Neuphoria Therapeutics Inc. on April 16, 2025.

Summary

• Peter Miles Winston Davies, a director of Neuphoria Therapeutics Inc., reported a transaction on April 16, 2025.
• Davies acquired 6,783 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of common stock each.
• The RSUs will fully vest at 5:01 PM EST on the day prior to the company's next annual shareholder meeting, expected no later than November 30, 2025, subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock units acquisition by a director, indicating alignment with the company's performance but not necessarily a strong positive or negative signal.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the director's continuous service to the company through the day prior to the next annual shareholder meeting, expected no later than November 30, 2025.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders can monitor insider transactions to gauge management's confidence in the company.

Key Dates

Keywords

Restricted Stock Units, RSU, Director, Beneficial Ownership, Neuphoria Therapeutics, NEUP, Form 4, Davies